Table 1.

Baseline clinical features in patients grouped by survival state

CharacteristicSurvivors (n=204)Nonsurvivors (n=77)P
Age, yr61 (54–67)69 (64–73)<0.001
Male111 (54.4)42 (54.6)0.98
Duration of hemodialysis, yr3.6 (1.1–8.7)4.5 (1.8–8.9)0.18
Smoking44 (21.6)15 (19.5)0.70
Cardiothoracic ratio49.0 (46.0–51.5)50.5 (48.5–55.0)<0.001
Left ventricular ejection fraction67.0 (58.0–72.0)64.0 (59.0–73.0)0.40
Diabetes92 (45.1)44 (57.1)0.07
Left ventricular hypertrophy96 (47.1)38 (49.4)0.73
Kt/V1.39±0.301.36±0.320.38
Hematocrit31.9 (30.1–34.0)32.4 (28.9–34.0)0.67
Albumin, g/dl3.7 (3.5–3.9)3.4 (3.2–3.7)<0.001
C-reactive protein, mg/L1.3 (0.6–4.0)4.8 (1.2–15.5)<0.001
Intact parathyroid hormone, pg/ml83 (37–171)109 (33–159)0.83
Triglyceride, mg/dl105 (75–150)92 (69–134)0.22
Total cholesterol, mg/dl168 (143–190)162 (137–199)0.77
HDL cholesterol, mg/dl42 (34–53)42 (34–50)0.54
LDL cholesterol, mg/dl96 (77–116)98 (76–119)0.75
Calcium, mg/L8.9 (8.4–9.5)8.9 (8.4–9.5)0.77
Phosphate, mg/L5.3±1.25.3±1.30.82
Calcium × phosphate, mg2/L247 (40–55)49 (41–56)0.61
Clinical history
 stroke16 (7.8)7 (9.1)0.73
 coronary artery disease52 (25.5)26 (33.8)0.16
 peripheral vascular disease9 (4.4)10 (13.0)0.01
Medication
β blockers35 (17.2)15 (19.5)0.64
 angiotensin converting enzyme inhibitors56 (27.5)20 (26.0)0.80
 angiotensin receptor blockers57 (27.9)16 (20.8)0.22
 calcium channel blockers115 (56.4)50 (64.9)0.19
Holter electrocardiography
 heart rate per min70.2±11.171.2±13.00.42
 atrial premature contraction per 24 h29 (9–105)125 (29–768)<0.001
 ventricular premature contraction per 24 h4 (1–41)12 (3–228)0.006
  • Data are n (%) for categorical data, median (interquartile range) for continuous normally distributed data, and mean ± SD for those not normally distributed.